Showing 15 posts of 30 posts found.


Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019
Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …

Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

February 15, 2019
Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …


Scotland recommends Roche’s Perjeta for HER2+ metastatic breast cancer

January 15, 2019
Manufacturing and Production, Sales and Marketing Breast cancer; Roche; Scotland, NHS, Perjeta, UK, pharma

Breast cancer patients in Scotland are set to receive an additional treatment option, as the Scottish Medicines Consortium announces its …


NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer

June 15, 2018
Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma

Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …

EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer

April 30, 2018
Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …


NICE approves Perjeta for routine use on NHS

February 1, 2018
Sales and Marketing Perjeta, Roche, biotech, drugs, pharma, pharmaceutical

NICE has given the nod to Roche’s Perjeta for routine first-line use, alongside Herceptin and chemotherapy, in patients with HER2-positive …


FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy

December 21, 2017
Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma

Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …


NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …


FDA awards Roche priority review in HER2-positive breast cancer

October 2, 2017
Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma, pharmaceutical

Roche has revealed that its monoclonal antibody Perjeta (pertuzumab) has been awarded priority review by the FDA as an adjuvant …


Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results

March 2, 2017
Research and Development Herceptin, Perjeta, Roche

Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …


NICE approves Roche’s Perjeta for breast cancer

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …


UK regulators do not back Roche’s breast cancer drug

May 20, 2016
Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation

The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …

Roche image

Roche oncology sales shine but profits dip

January 29, 2015
Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4

Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …

Roche image

Roche dealt with two late-stage blows

December 19, 2014
Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine

Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …

Kadcyla image

Global drug spending set to top $1 trillion

November 20, 2014
Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend

Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …

Latest content